NCT06745583View on ClinicalTrials.gov

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Mild, Moderate, or Severe Alzheimer's Disease
Interventions
DRUG

EI-1071 tablet, oral

Dose: 448.2 mg BID for 28 days

Trial Locations (2)

112

RECRUITING

Taipei Veterans General Hospital, Taipei

11490

NOT_YET_RECRUITING

Tri-Service General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Elixiron Immunotherapeutics (Hong Kong) Ltd.

INDUSTRY

NCT06745583 - A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | Biotech Hunter | Biotech Hunter